Indivior Q4 Earnings Exceed Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy INDV?
Source: seekingalpha
- Strong Earnings Report: Indivior reported a Q4 non-GAAP EPS of $0.82, beating expectations by $0.15, which demonstrates robust profitability growth and enhances investor confidence in the company's performance.
- Significant Revenue Growth: The company achieved Q4 revenue of $358 million, representing a 20.1% year-over-year increase and exceeding market expectations by $52.38 million, indicating strong demand and sales performance.
- 2026 Financial Guidance: Indivior projects net revenue for 2026 to be between $1.125 billion and $1.195 billion, with SUBLOCADE net revenue expected to range from $905 million to $945 million, reflecting confidence in future growth and strategic planning.
- Cost Control Measures: The company anticipates non-GAAP operating expenses to be between $430 million and $450 million, with adjusted EBITDA projected at $535 million to $575 million, showcasing ongoing efforts in cost management and profitability enhancement.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INDV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INDV
Wall Street analysts forecast INDV stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 33.340
Low
36.00
Averages
43.75
High
50.00
Current: 33.340
Low
36.00
Averages
43.75
High
50.00
About INDV
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Divisadero Exits Entire Position in Stride
- Position Change: Divisadero Street Capital Management sold 375,000 shares of Stride in Q4 2025, previously valued at $55.9 million and representing 2.4% of its reported assets, indicating a cautious outlook on the company's future performance.
- Stock Volatility: As of February 13, 2026, Stride's stock price was $84.89, down 39.1% over the past year, significantly trailing the S&P 500 by 50.8 percentage points, reflecting market concerns about its growth prospects.
- Performance Decline: Stride reported only 7.5% year-over-year revenue growth in Q4, a notable decline from prior quarters, and faced stock volatility due to a platform issue that disrupted customer experience, potentially shaking investor confidence despite resolution.
- Revenue Guidance: Despite challenges, Stride reaffirmed its full-year revenue guidance of $2.48 billion to $2.555 billion, slightly up from $2.4 billion in the previous fiscal year, demonstrating the company's confidence in future performance.
See More
Divisadero Exits Entire Position in Stride
- Complete Exit: Divisadero Street Capital Management sold its entire position in Stride during Q4 2025, offloading 375,000 shares and resulting in a $55.9 million decrease in position value, indicating a significant loss of confidence in the company.
- Asset Allocation Shift: Stride previously accounted for 2.4% of Divisadero's reported assets, but the latest 13F filing as of December 31, 2025, shows no holdings in Stride, reflecting a major shift in investment strategy.
- Slowing Growth: Stride reported only 7.5% year-over-year revenue growth in Q4, a notable decline from previous quarters, and faced platform issues that disrupted customer experience, shaking investor confidence despite management's claims of robust demand.
- Future Guidance: Despite challenges, Stride reaffirmed its full-year revenue guidance of $2.480 billion to $2.555 billion, slightly above last year's $2.4 billion, demonstrating the company's resilience and strategic adaptability in a volatile market.
See More
Indivior Pharmaceuticals Reports Q4 2025 Earnings Highlights
- Financial Performance Growth: Indivior achieved total net revenue of $1.24 billion in 2025, a 4% year-over-year increase, with SUBLOCADE net revenue reaching $856 million, reflecting a 13% growth from 2024, indicating strong market performance and sustained growth potential.
- Share Repurchase Program: The company announced a new $400 million share repurchase program aimed at enhancing shareholder value while completing a $295 million DOJ obligation payment in 2025, further optimizing its financial structure.
- Optimistic Future Outlook: Indivior reaffirmed its 2026 total net revenue guidance in the range of $1.125 billion to $1.195 billion, with projected SUBLOCADE net revenue growth of 8%, reflecting confidence in future market demand.
- Operational Efficiency Improvement: Adjusted EBITDA for Q4 increased by 91% to $142 million, with full-year EBITDA rising 20% to $428 million, showcasing significant improvements in cost control and operational efficiency.
See More
Indivior Q4 Earnings Exceed Expectations
- Strong Earnings Report: Indivior reported a Q4 non-GAAP EPS of $0.82, beating expectations by $0.15, which demonstrates robust profitability growth and enhances investor confidence in the company's performance.
- Significant Revenue Growth: The company achieved Q4 revenue of $358 million, representing a 20.1% year-over-year increase and exceeding market expectations by $52.38 million, indicating strong demand and sales performance.
- 2026 Financial Guidance: Indivior projects net revenue for 2026 to be between $1.125 billion and $1.195 billion, with SUBLOCADE net revenue expected to range from $905 million to $945 million, reflecting confidence in future growth and strategic planning.
- Cost Control Measures: The company anticipates non-GAAP operating expenses to be between $430 million and $450 million, with adjusted EBITDA projected at $535 million to $575 million, showcasing ongoing efforts in cost management and profitability enhancement.
See More
Kevin Mahn Advises Investors to Focus on Long-Term Growth Amid Market Volatility
- Market Volatility Impact: Kevin Mahn highlighted that in 2025, markets initially fell nearly 15% due to tariff fears, but those who remained invested saw a 39% rebound by year-end, underscoring the risks of reacting to short-term headlines.
- Identifying Investment Opportunities: Mahn advised investors to focus on long-term growth, particularly the AI boom, with trillions expected in infrastructure investments by 2030, emphasizing the potential of companies supporting this growth, such as data center cooling and power providers.
- Stability and Yield: He mentioned Comfort Systems USA Inc., recently added to the S&P 500, and Duke Energy Corp., trading at 17X forward earnings with a 3.7% dividend yield, as solid choices for stability in turbulent markets.
- Sector Outlook: Mahn also pointed out promising sectors like aerospace and defense, driven by rising global military budgets, and small-cap biotech, benefiting from patent cliffs and M&A activity, recommending companies like L3 Harris and Indivior as investment targets.
See More
Healthcare Sector Outperforms S&P 500 with 12.52% Gain and 3.20 Health Score
- Sector Performance: The S&P 500 healthcare sector achieved a 12.52% gain in 2025, lagging behind the broader S&P 500 index's 16.39% increase, indicating relative strength within the healthcare industry.
- Health Score Analysis: Seeking Alpha's Quant Ratings assign an average health score of 3.20 out of 5 to the healthcare sector, based on 261 stocks with market capitalizations above $2 billion, reflecting a generally healthy outlook for the sector.
- Stock Rating Distribution: Among the 261 stocks, 37 are rated Buy or higher, 213 are Neutral, and 11 are Strong Sell, showcasing varied market perceptions and investment opportunities within the healthcare sector.
- Top Stock Ratings: Ahead of the upcoming earnings season, stocks like Grail (GRAL) and Indivior PLC (INDV) received strong buy ratings of 4.97 and 4.95, respectively, indicating strong investor confidence in these companies.
See More
Divisadero Exits Entire Position in Stride
- Position Change: Divisadero Street Capital Management sold 375,000 shares of Stride in Q4 2025, previously valued at $55.9 million and representing 2.4% of its reported assets, indicating a cautious outlook on the company's future performance.
- Stock Volatility: As of February 13, 2026, Stride's stock price was $84.89, down 39.1% over the past year, significantly trailing the S&P 500 by 50.8 percentage points, reflecting market concerns about its growth prospects.
- Performance Decline: Stride reported only 7.5% year-over-year revenue growth in Q4, a notable decline from prior quarters, and faced stock volatility due to a platform issue that disrupted customer experience, potentially shaking investor confidence despite resolution.
- Revenue Guidance: Despite challenges, Stride reaffirmed its full-year revenue guidance of $2.48 billion to $2.555 billion, slightly up from $2.4 billion in the previous fiscal year, demonstrating the company's confidence in future performance.
See More
Divisadero Exits Entire Position in Stride
- Complete Exit: Divisadero Street Capital Management sold its entire position in Stride during Q4 2025, offloading 375,000 shares and resulting in a $55.9 million decrease in position value, indicating a significant loss of confidence in the company.
- Asset Allocation Shift: Stride previously accounted for 2.4% of Divisadero's reported assets, but the latest 13F filing as of December 31, 2025, shows no holdings in Stride, reflecting a major shift in investment strategy.
- Slowing Growth: Stride reported only 7.5% year-over-year revenue growth in Q4, a notable decline from previous quarters, and faced platform issues that disrupted customer experience, shaking investor confidence despite management's claims of robust demand.
- Future Guidance: Despite challenges, Stride reaffirmed its full-year revenue guidance of $2.480 billion to $2.555 billion, slightly above last year's $2.4 billion, demonstrating the company's resilience and strategic adaptability in a volatile market.
See More
Indivior Pharmaceuticals Reports Q4 2025 Earnings Highlights
- Financial Performance Growth: Indivior achieved total net revenue of $1.24 billion in 2025, a 4% year-over-year increase, with SUBLOCADE net revenue reaching $856 million, reflecting a 13% growth from 2024, indicating strong market performance and sustained growth potential.
- Share Repurchase Program: The company announced a new $400 million share repurchase program aimed at enhancing shareholder value while completing a $295 million DOJ obligation payment in 2025, further optimizing its financial structure.
- Optimistic Future Outlook: Indivior reaffirmed its 2026 total net revenue guidance in the range of $1.125 billion to $1.195 billion, with projected SUBLOCADE net revenue growth of 8%, reflecting confidence in future market demand.
- Operational Efficiency Improvement: Adjusted EBITDA for Q4 increased by 91% to $142 million, with full-year EBITDA rising 20% to $428 million, showcasing significant improvements in cost control and operational efficiency.
See More
Indivior Q4 Earnings Exceed Expectations
- Strong Earnings Report: Indivior reported a Q4 non-GAAP EPS of $0.82, beating expectations by $0.15, which demonstrates robust profitability growth and enhances investor confidence in the company's performance.
- Significant Revenue Growth: The company achieved Q4 revenue of $358 million, representing a 20.1% year-over-year increase and exceeding market expectations by $52.38 million, indicating strong demand and sales performance.
- 2026 Financial Guidance: Indivior projects net revenue for 2026 to be between $1.125 billion and $1.195 billion, with SUBLOCADE net revenue expected to range from $905 million to $945 million, reflecting confidence in future growth and strategic planning.
- Cost Control Measures: The company anticipates non-GAAP operating expenses to be between $430 million and $450 million, with adjusted EBITDA projected at $535 million to $575 million, showcasing ongoing efforts in cost management and profitability enhancement.
See More
Kevin Mahn Advises Investors to Focus on Long-Term Growth Amid Market Volatility
- Market Volatility Impact: Kevin Mahn highlighted that in 2025, markets initially fell nearly 15% due to tariff fears, but those who remained invested saw a 39% rebound by year-end, underscoring the risks of reacting to short-term headlines.
- Identifying Investment Opportunities: Mahn advised investors to focus on long-term growth, particularly the AI boom, with trillions expected in infrastructure investments by 2030, emphasizing the potential of companies supporting this growth, such as data center cooling and power providers.
- Stability and Yield: He mentioned Comfort Systems USA Inc., recently added to the S&P 500, and Duke Energy Corp., trading at 17X forward earnings with a 3.7% dividend yield, as solid choices for stability in turbulent markets.
- Sector Outlook: Mahn also pointed out promising sectors like aerospace and defense, driven by rising global military budgets, and small-cap biotech, benefiting from patent cliffs and M&A activity, recommending companies like L3 Harris and Indivior as investment targets.
See More
Healthcare Sector Outperforms S&P 500 with 12.52% Gain and 3.20 Health Score
- Sector Performance: The S&P 500 healthcare sector achieved a 12.52% gain in 2025, lagging behind the broader S&P 500 index's 16.39% increase, indicating relative strength within the healthcare industry.
- Health Score Analysis: Seeking Alpha's Quant Ratings assign an average health score of 3.20 out of 5 to the healthcare sector, based on 261 stocks with market capitalizations above $2 billion, reflecting a generally healthy outlook for the sector.
- Stock Rating Distribution: Among the 261 stocks, 37 are rated Buy or higher, 213 are Neutral, and 11 are Strong Sell, showcasing varied market perceptions and investment opportunities within the healthcare sector.
- Top Stock Ratings: Ahead of the upcoming earnings season, stocks like Grail (GRAL) and Indivior PLC (INDV) received strong buy ratings of 4.97 and 4.95, respectively, indicating strong investor confidence in these companies.
See More
